| 1 | home randomize rationale and | | | | | | | 1 | 0.51% |
| 2 | artery stenosis50 or occlusion | | | | | | | 1 | 0.51% |
| 3 | stroke with a tandem | | | | | | | 1 | 0.51% |
| 4 | with a tandem lesion | | | | | | | 1 | 0.51% |
| 5 | a tandem lesion ipsilateral | | | | | | | 1 | 0.51% |
| 6 | tandem lesion ipsilateral proximal | | | | | | | 1 | 0.51% |
| 7 | atherosclerotic internal carotid artery | | | | | | | 1 | 0.51% |
| 8 | internal carotid artery stenosis50 | | | | | | | 1 | 0.51% |
| 9 | carotid artery stenosis50 or | | | | | | | 1 | 0.51% |
| 10 | immediate carotid artery stenting | | | | | | | 1 | 0.51% |
| 11 | treatment for an acute | | | | | | | 1 | 0.51% |
| 12 | carotid artery stenting a | | | | | | | 1 | 0.51% |
| 13 | artery stenting a deferred | | | | | | | 1 | 0.51% |
| 14 | stenting a deferred treatment | | | | | | | 1 | 0.51% |
| 15 | a deferred treatment approach | | | | | | | 1 | 0.51% |
| 16 | carotid revascularization within two | | | | | | | 1 | 0.51% |
| 17 | revascularization within two weeks | | | | | | | 1 | 0.51% |
| 18 | within two weeks after | | | | | | | 1 | 0.51% |
| 19 | ischemic stroke with a | | | | | | | 1 | 0.51% |
| 20 | endovascular treatment for an | | | | | | | 1 | 0.51% |
| 21 | weeks after stroke onset | | | | | | | 1 | 0.51% |
| 22 | assess the efficacy and | | | | | | | 1 | 0.51% |
| 23 | trial performed within the | | | | | | | 1 | 0.51% |
| 24 | performed within the contrast | | | | | | | 1 | 0.51% |
| 25 | within the contrast consortium | | | | | | | 1 | 0.51% |
| 26 | the contrast consortium the | | | | | | | 1 | 0.51% |
| 27 | aim is to assess | | | | | | | 1 | 0.51% |
| 28 | is to assess the | | | | | | | 1 | 0.51% |
| 29 | to assess the efficacy | | | | | | | 1 | 0.51% |
| 30 | the efficacy and safety | | | | | | | 1 | 0.51% |
| 31 | undergoing endovascular treatment for | | | | | | | 1 | 0.51% |
| 32 | efficacy and safety of | | | | | | | 1 | 0.51% |
| 33 | and safety of two | | | | | | | 1 | 0.51% |
| 34 | randomize rationale and aim | | | | | | | 1 | 0.51% |
| 35 | of two different treatment | | | | | | | 1 | 0.51% |
| 36 | strategies in patients undergoing | | | | | | | 1 | 0.51% |
| 37 | in patients undergoing endovascular | | | | | | | 1 | 0.51% |
| 38 | patients undergoing endovascular treatment | | | | | | | 1 | 0.51% |
| 39 | two weeks after stroke | | | | | | | 1 | 0.51% |
| 40 | after stroke onset or | | | | | | | 1 | 0.51% |